UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 8, 2004
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-21696 22-3106987
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
26 Landsdowne Street, Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 494-0400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02 Results of Operations and Financial Condition
On November 8, 2004, ARIAD Pharmaceuticals, Inc. announced its
financial results for the period ended September 30, 2004. A copy of
the press release is furnished pursuant to this Item 2.02 as Exhibit
99.1 to this Current Report on Form 8-K.
ITEM 8.01 Other Events.
In its press release dated November 8, 2004, ARIAD Pharmaceuticals,
Inc. provided an overview of the clinical development of AP23573 and
other matters under the headings "AP23573 Update", "Business
Strategy" and "Upcoming Events". The Company hereby incorporates
such information by reference into this Item 8.01 of this Current
Report on Form 8-K.
ITEM 9.01 Financial Statements and Exhibits.
(c) Exhibits
Exhibit
Number Description
-------- -----------
99.1 Press release dated November 8, 2004.
The portions of the Press Release incorporated by reference
into Item 8.01 of this Current Report on Form 8-K are being
filed pursuant to Item 8.01. The remaining portions of the
Press Release are being furnished pursuant to Item 2.02 of
this Current Report on Form 8-K and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange
Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that Section, nor shall it be deemed
incorporated by reference in any filing under the Securities
Act of 1933 or the Exchange Act.
2
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ARIAD Pharmaceuticals, Inc.
By: /s/ Edward M. Fitzgerald
---------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: November 8, 2004
3
EXHIBIT INDEX
Exhibit
Number Description
99.1 Press release dated November 8, 2004.
4